Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 243
- Registration Number
- NCT03018028
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 458
- Registration Number
- NCT03015220
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yamato-shi, Kanagawa, Japan
A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 41
- Registration Number
- NCT03010475
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 320
- Registration Number
- NCT02970942
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.
- Conditions
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 45
- Registration Number
- NCT02920385
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 703
- Registration Number
- NCT02906930
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 55
- Registration Number
- NCT02877355
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 711
- Registration Number
- NCT02863419
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 822
- Registration Number
- NCT02863328
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 504
- Registration Number
- NCT02849080
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Rize, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.